Cambridge Healthtech Institute’s Inaugural
Analytical Characterisation
Implementing New Technologies and Enhancing Analytical Strategies
March 24-25, 2020
Bioprocessing Summit Europe is excited to announce the launch of a new conference stream dedicated to the Analytical Characterisation of Biotherapeutics. We bring together leading scientists from the biopharmaceutical industry, academia and government to discuss novel characterisation methods, tools and technologies. Join us in Barcelona to improve your analytical strategies across all phases of development and production.
Preliminary Agenda
From Sample to Project Decision: Fully Automating MS Analytics of Next-Generation Protein Therapeutics
Miroslav Nikolov, PhD, Senior Scientist & Lab Head, Roche Pharma Research and Early Development (pRED)
The Delights of Diversity: Application of Native MS in a Biopharmaceutical Development Lab
Dan Bach Kristensen, PhD, Principal Scientist, Symphogen
Using Intrinsic Fluorescence Emission for Analysis of Cell Culture Media and Protein-Based Samples
Alan G. Ryder, PhD, Professor, Nanoscale Biophotonics Laboratory, National University of Ireland Galway
Talk Title to be Announced
Jonathan Bones, PhD, Principal Investigator, CCL, National Institute for Bioprocessing Research and Training (NIBRT)
Genetic Stability Strategies for Developing Vaccines from Early Phase Development to a Commercial Product
Gerard Scheppink, Scientist, Product Characterisation/Analytical Development, Janssen Vaccines
New International Standards for New Challenges: Supporting Monoclonal Antibody Product Consistency in the Era of Biosimilars
Sandra Prior, PhD, Senior Scientist, National Institute for Biological Standards and Control (NIBSC, a centre of the MHRA)
Advanced Therapies: Ongoing Efforts in Setting Standard for Cell and Gene Therapies
Fouad Atouf, PhD, Vice President, Global Biologics, U.S. Pharmacopeia
Cell Population and Fingerprint Analysis for Decision Making along the Bioprocess Chain of ADCs and Biosimilars
Christoph Herwig, PhD, Head Research Area Biochemical Engineering, TU Vienna
HCP Immunoassays and
Orthogonal Methods for Identification of HCP Impurities in Downstream Samples
Eric Bishop Vice President
of Research and Development Research and Development Cygnus Technologies
Analytical Characterisation of Novel High Potency Neurotoxin Therapeutics
David Spencer, Characterisation Manager, Ipsen Biopharm
Development of Bioassays for Bispecifics
Sachin Dubey, PhD, Deputy Director/Head, Formulation, Analytical and Drug Production Development, Glenmark Pharmaceuticals SA
For more details on the conference, please contact:
Gemma Smith
Senior Conference Director
Cambridge Healthtech Institute
Phone: +447754.518.131
Email: gsmith@cambridgeinnovationinstitute.com
For partnering and sponsorship information, please contact:
Companies A-K
Sherry Johnson
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-1359
Email: sjohnson@cambridgeinnovationinstitute.com
Companies L-Z
Carolyn Cooke
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-972-5412
Email: ccooke@healthtech.com